Bear,

this Ozempic drug seems to have done everything that Apabetalone was supposed to do.  26% reduction in MACE for DM2 patients with CVD.  Is this a death kneel for Apabetalone when it comes to CVD indication?  I mean the FDA is keen to have at least one drug for any one indication...so will it cool the FDA's desire to get our drug on the market fast...at least as far as CVD is concerned?

When I read about Ozempic, my first reaction is that forget CVD and focus on renal.  

Your thoughts?

Iconoclast